116 related articles for article (PubMed ID: 29774106)
1. Hematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice.
Tarnawsky SP; Yu WM; Qu CK; Chan RJ; Yoder MC
Oncotarget; 2018 Apr; 9(31):21831-21843. PubMed ID: 29774106
[TBL] [Abstract][Full Text] [Related]
2. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
3. JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β.
Yan Y; Dong L; Chen C; Bunting KD; Li Q; Stieglitz E; Loh ML; Qu CK
Blood Adv; 2022 Jan; 6(1):200-206. PubMed ID: 34555844
[TBL] [Abstract][Full Text] [Related]
4. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
5. Mice expressing KrasG12D in hematopoietic multipotent progenitor cells develop neonatal myeloid leukemia.
Tarnawsky SP; Kobayashi M; Chan RJ; Yoder MC
J Clin Invest; 2017 Oct; 127(10):3652-3656. PubMed ID: 28846072
[TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Gupta AK; Meena JP; Chopra A; Tanwar P; Seth R
Am J Blood Res; 2021; 11(1):1-21. PubMed ID: 33796386
[TBL] [Abstract][Full Text] [Related]
7. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Akutagawa J; Huang TQ; Epstein I; Chang T; Quirindongo-Crespo M; Cottonham CL; Dail M; Slusher BS; Friedman LS; Sampath D; Braun BS
Leukemia; 2016 Jun; 30(6):1335-43. PubMed ID: 26965285
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A; Horstmann MA; Fehse B; Ortmeyer G; Niemeyer CM; Stocking C; Mayr GW; Jücker M
Gene Ther; 2007 Apr; 14(8):699-703. PubMed ID: 17268534
[TBL] [Abstract][Full Text] [Related]
10. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
13. Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia.
Loh ML
Hematology Am Soc Hematol Educ Program; 2010; 2010():357-62. PubMed ID: 21239819
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia.
Emanuel PD
Curr Hematol Rep; 2004 May; 3(3):203-9. PubMed ID: 15087069
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Profiling of
Sinha R; Dvorak M; Ganesan A; Kalesinskas L; Niemeyer CM; Flotho C; Sakamoto KM; Lacayo N; Patil RV; Perriman R; Cepika AM; Liu YL; Kuo A; Utz PJ; Khatri P; Bertaina A
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958378
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
[TBL] [Abstract][Full Text] [Related]
18. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
19. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
Jakovljević G; Kardum-Skelin I; Rogosić S; Nakić M
Coll Antropol; 2010 Mar; 34(1):251-4. PubMed ID: 20432758
[TBL] [Abstract][Full Text] [Related]
20. In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.
Chang BH; Thiel-Klare K; Tyner JW
bioRxiv; 2024 May; ():. PubMed ID: 38798550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
